Drug Profile
Research programme: botanic anticancer therapeutics - JoBen Bio-Medical/Development Center for Biotechnology
Alternative Names: JBM-AC01Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Joben Bio-Medical
- Developer Development Center for Biotechnology; Joben Bio-Medical
- Class Anti-inflammatories; Antineoplastics; Herbal medicines; Traditional Chinese medicine
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; Proto oncogene protein c-akt inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Taiwan (PO, Pill)